Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

Table 4

Results of the base-case analysis for a 65-year-old population over a time horizon of 20 years from a German healthcare insurance perspective.

Trial	Anticoagulant	QALY	Total costs	ICER; /QALY	Daily price; /d	PSA ICER; /QALY
ENGAGE-AF	Edoxaban 30 mg od	7.65	21 052	68 275	3.37	69 600
	Warfarin	7.48	9 747		0.20
	Edoxaban 60 mg od	7.69	20 157	50 411	3.37	52 000
	Warfarin	7.48	9 747		0.20
RE-LY [5]	Dabigatran 110 mg bid	7.68	20 048	294 349	3.38	278 000
	Warfarin	7.64	7 622		0.20
	Dabigatran 150 mg bid	7.71	19 537	163 184	3.38	174 000
	Warfarin	7.64	7 622		0.20
ROCKET-AF [5]	Rivaroxaban 20 mg od	7.67	19 874	133 926	3.20	130 500
	Warfarin	7.59	9 069		0.20
ARISTOTLE [5]	Apixaban 5 mg bid	7.75	19 885	57 245	3.54	55 500
	Warfarin	7.56	8 915		0.20